This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

3 Things To Watch For With Arena Pharmaceuticals

Stocks in this article: ARNA VVUS

When Jefferies released a research note for Arena Pharmaceuticals (ARNA) with a target price of $12, shares subsequently fell to around $6.90 since the analysis. Similar to other pharmaceutical plays, Arena traded higher ahead of the release of weight-loss drug Belviq on the market. Obesity is a growing problem, and Belviq has a large market to address, but whether the value of the company will be driven upwards depends on a few key results.

[Read more from Kapitall: 6 Cash-Rich Healthcare Stocks Look Undervalued‚Äč]

Results to Watch

Investors should watch the following before asserting a more positive sentiment on Arena:

1.     Weekly prescriptions for Belviq

2.     Effective advertising

3.     Rising coverage for Belviq from insurance companies

In the near term, short sellers could dictate the depressed share price for Arena. Short float is around 28%. Bets against Arena have risen steadily since April. The only time short selling declined was between April 15 and April 30, 2013:

Screen Shot 2013-07-29 at 4.13.14 PM











Alternative Investments

Vivus (VVUS) is often considered as an alternative investment to Arena. Bearishness for Vivus is also high, with short float at 29.4%. Vivus recently released Qsymia, and scripts for the obesity drug could be growing. Regardless of the actual rate of prescriptions, both Qsymia and Belviq should experience stronger sales in the future. It takes time for the market to gain acceptance of a new drug in the market. Other companies in the pharmaceutical space to research are illustrated in the chart below:

<p>Your browser does not support iframes.</p>

Disclosure: Author has a long position in Arena Pharmaceuticals


Written by  Chris Lau, Kapitall contributor. Monthly returns sourced from Zacks Investment Research. 


Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs